Upcoming events participation

Poolbeg Pharma

21/10/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221021:nRSU6339Da&default-theme=true

RNS Number : 6339D  Poolbeg Pharma PLC  21 October 2022

 

Poolbeg Pharma plc

 

Upcoming Events

 

21 October 2022 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF), a clinical stage
infectious disease pharmaceutical company with a capital light clinical model,
announces that its management and business development team will be attending
and presenting at a number upcoming partnering and investor events from
October 2022 to January 2023.

 

Partnering events

 •    BIO-Europe from 24-26 October 2022 at Leipzig Messe, Leipzig, Germany 04356
 •    Jefferies London Healthcare Conference from 15-17 November 2022 in London
 •    JP Morgan 41(st) Annual Healthcare Conference from 9-12 January 2023 at the
      Westin St. Francis Hotel, San Francisco, CA

 

Investor events

 •    London South East Webinar (virtual) on 8 November 2022. Register here
      (https://www.lse.co.uk/events/)
 •    LSX Inv€$tival Showcase(TM) on 14 November 2022 at Old Billingsgate, London
      EC3R 6DX. Poolbeg CEO, Jeremy Skillington, will present at 14:15 on Stage 4:
      Biotech Late Growth. Register here
      (https://www.lsxleaders.com/investival-showcase)

 

Event details may be subject to change - further information and updates are
available on the Poolbeg Pharma website here
(https://www.poolbegpharma.com/investors/events-presentations/) .

- Ends -

Enquiries

 

 Poolbeg Pharma Plc                                   +44 (0) 20 7183 1499

 Jeremy Skillington, CEO

 Ian O'Connell, CFO

 finnCap Ltd (Nominated Adviser & Joint Broker)      +44 (0) 20 7220 0500

 Geoff Nash, James Thompson, Charlie Beeson

 Nigel Birks, Harriet Ward (ECM)

 Singer Capital Markets (Joint Broker)               +44 (0) 20 7496 3000

 Phil Davies, Sam Butcher

 J&E Davy (Joint Broker)                             +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

 Instinctif Partners                                 +44 (0) 20 7457 2020

 Melanie Toyne Sewell, Rozi Morris, Tim Field        poolbeg@instinctif.com (mailto:poolbeg@instinctif.com)

About Poolbeg Pharma

Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company,
with a unique capital light clinical model which aims to develop multiple
products faster and more cost effectively than the conventional biotech model.
The Company, headquartered in London, is led by a team with a track record of
creation and delivery of shareholder value and aspires to become a "one-stop
shop" for pharma and biotech seeking mid-stage products to license or acquire.

 

The Company is targeting the growing infectious disease market. In the wake of
the COVID-19 pandemic, infectious disease has become one of the fastest
growing pharma markets and is expected to exceed $250bn by 2025.

 

With its initial assets from Open Orphan plc (https://www.openorphan.com/) ,
an industry leading infectious disease and human challenge trials business,
Poolbeg has access to knowledge, experience, and clinical data from over 20
years of human challenge trials. The Company is using these insights to
acquire new assets as well as reposition clinical stage products, reducing
spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small
molecule immunomodulator for severe influenza (POLB 001) which has commenced
its LPS human challenge trial with initial results expected by year end 2022;
a first-in-class, intranasally administered RNA-based immunotherapy for
respiratory virus infections (POLB 002); and a vaccine candidate for
Melioidosis (POLB 003). The Company is also developing an oral vaccine
delivery platform and is progressing two artificial intelligence (AI)
programmes to accelerate the power of its human challenge model data and
biobank, with results from the first programme expected by year end 2022.

 

For more information, please go to www.poolbegpharma.com
(http://www.poolbegpharma.com/)  or follow us on Twitter
(https://twitter.com/PoolbegPharma)  and LinkedIn
(https://www.linkedin.com/company/poolbeg-pharma/)  @PoolbegPharma.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADZMZGNGRGZZM